Progestogen-only injectable hormonal contraceptive use should be considered in analysis of studies addressing the loss of bone mineral density in HIV-positive women

J Acquir Immune Defic Syndr. 2010 Aug;54(4):e5. doi: 10.1097/QAI.0b013e3181e49462.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Bone Density / drug effects*
  • Bone Resorption / etiology
  • Contraceptives, Oral, Hormonal / administration & dosage
  • Contraceptives, Oral, Hormonal / therapeutic use
  • Delayed-Action Preparations / adverse effects
  • Delayed-Action Preparations / therapeutic use
  • Female
  • HIV Seropositivity / physiopathology*
  • Humans
  • Injections
  • Progestins / administration & dosage
  • Progestins / adverse effects
  • Progestins / therapeutic use*
  • United States
  • United States Food and Drug Administration

Substances

  • Contraceptives, Oral, Hormonal
  • Delayed-Action Preparations
  • Progestins